Skip to Content
Merck
CN
  • Genetic architecture of vitamin B12 and folate levels uncovered applying deeply sequenced large datasets.

Genetic architecture of vitamin B12 and folate levels uncovered applying deeply sequenced large datasets.

PLoS genetics (2013-06-12)
Niels Grarup, Patrick Sulem, Camilla H Sandholt, Gudmar Thorleifsson, Tarunveer S Ahluwalia, Valgerdur Steinthorsdottir, Helgi Bjarnason, Daniel F Gudbjartsson, Olafur T Magnusson, Thomas Sparsø, Anders Albrechtsen, Augustine Kong, Gisli Masson, Geng Tian, Hongzhi Cao, Chao Nie, Karsten Kristiansen, Lise Lotte Husemoen, Betina Thuesen, Yingrui Li, Rasmus Nielsen, Allan Linneberg, Isleifur Olafsson, Gudmundur I Eyjolfsson, Torben Jørgensen, Jun Wang, Torben Hansen, Unnur Thorsteinsdottir, Kari Stefánsson, Oluf Pedersen
ABSTRACT

Genome-wide association studies have mainly relied on common HapMap sequence variations. Recently, sequencing approaches have allowed analysis of low frequency and rare variants in conjunction with common variants, thereby improving the search for functional variants and thus the understanding of the underlying biology of human traits and diseases. Here, we used a large Icelandic whole genome sequence dataset combined with Danish exome sequence data to gain insight into the genetic architecture of serum levels of vitamin B(12) (B12) and folate. Up to 22.9 million sequence variants were analyzed in combined samples of 45,576 and 37,341 individuals with serum B(12) and folate measurements, respectively. We found six novel loci associating with serum B(12) (CD320, TCN2, ABCD4, MMAA, MMACHC) or folate levels (FOLR3) and confirmed seven loci for these traits (TCN1, FUT6, FUT2, CUBN, CLYBL, MUT, MTHFR). Conditional analyses established that four loci contain additional independent signals. Interestingly, 13 of the 18 identified variants were coding and 11 of the 13 target genes have known functions related to B(12) and folate pathways. Contrary to epidemiological studies we did not find consistent association of the variants with cardiovascular diseases, cancers or Alzheimer's disease although some variants demonstrated pleiotropic effects. Although to some degree impeded by low statistical power for some of these conditions, these data suggest that sequence variants that contribute to the population diversity in serum B(12) or folate levels do not modify the risk of developing these conditions. Yet, the study demonstrates the value of combining whole genome and exome sequencing approaches to ascertain the genetic and molecular architectures underlying quantitative trait associations.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Vitamin B12, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
Vitamin B12, ≥98%
Sigma-Aldrich
Folic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥97%
Sigma-Aldrich
Cyanocobalamin, meets USP testing specifications
Supelco
Cyanocobalamin (B12), analytical standard
Folic acid, European Pharmacopoeia (EP) Reference Standard
Supelco
Cyanocobalamin, pharmaceutical secondary standard, certified reference material
Supelco
Folic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Folic acid, ≥97%
Sigma-Aldrich
Folic acid, meets USP testing specifications
Supelco
Cyanocobalamin (Vitamin B12) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Folic acid, Vetec, reagent grade, ≥97%